niontix 100% medicinski plin, ukapljeni
linde gas a.s., u technoplynu 1324, prag 9, Češka - dušikov (ii) oksid - medicinski plin, ukapljeni - 100% (v/v) - urbroj: dušikov oksid 100% (v/v)
crusia 10000 iu (100 mg)/1 ml otopina za injekciju u napunjenoj štrcaljki
laboratorios farmaceuticos rovi s.a., julian camarillo, 35, madrid, Španjolska - enoksaparinnatrij - otopina za injekciju u napunjenoj štrcaljki - 10000 iu (100 mg)/1 ml - urbroj: jedna napunjena štrcaljka sadrži 10000 iu anti-xa aktivnosti enoksaparinnatrija (što odgovara 100 mg) u 1,0 ml vode za injekcije
crusia 2000 iu (20 mg)/0,2 ml otopina za injekciju u napunjenoj štrcaljki
laboratorios farmaceuticos rovi s.a., julian camarillo, 35, madrid, Španjolska - enoksaparinnatrij - otopina za injekciju u napunjenoj štrcaljki - 2000 iu (20 mg)/0,2 ml - urbroj: jedna napunjena štrcaljka sadrži 2000 iu anti-xa aktivnosti enoksaparinnatrija (što odgovara 20 mg) u 0,2 ml vode za injekcije
crusia 4000 iu (40 mg)/0,4 ml otopina za injekciju u napunjenoj štrcaljki
laboratorios farmaceuticos rovi s.a., julian camarillo, 35, madrid, Španjolska - enoksaparinnatrij - otopina za injekciju u napunjenoj štrcaljki - 4000 iu (40 mg)/0,4 ml - urbroj: jedna napunjena štrcaljka sadrži 4000 iu anti-xa aktivnosti enoksaparinnatrija (što odgovara 40 mg) u 0,4 ml vode za injekcije
crusia 6000 iu (60 mg)/0,6 ml otopina za injekciju u napunjenoj štrcaljki
laboratorios farmaceuticos rovi s.a., julian camarillo, 35, madrid, Španjolska - enoksaparinnatrij - otopina za injekciju u napunjenoj štrcaljki - 6000 iu (60 mg)/0,6 ml - urbroj: jedna napunjena štrcaljka sadrži 6000 iu anti-xa aktivnosti enoksaparinnatrija (što odgovara 60 mg) u 0,6 ml vode za injekcije
crusia 8000 iu (80 mg)/0,8 ml otopina za injekciju u napunjenoj štrcaljki
laboratorios farmaceuticos rovi s.a., julian camarillo, 35, madrid, Španjolska - enoksaparinnatrij - otopina za injekciju u napunjenoj štrcaljki - 8000 iu (80 mg)/0,8 ml - urbroj: jedna napunjena štrcaljka sadrži 8000 iu anti-xa aktivnosti enoksaparinnatrija (što odgovara 80 mg) u 0,8 ml vode za injekcije
azot suboksid messer 100 % v/v/1 inhalacija medicinski gas, djelimicno tečni
messer tehnoplin d.o.o - azot suboksid - medicinski gas, djelimicno tečni - 100 % v/v/1 inhalacija - medicinski gas, djelimično tečni sadrži 100 % (v/v) azotsuboksida
azot suboksid messer 100 % v/v/1 inhalacija medicinski gas, djelimicno tečni
messer tehnoplin d.o.o - azot suboksid - medicinski gas, djelimicno tečni - 100 % v/v/1 inhalacija - medicinski gas, djelimično tečni sadrži 100 % (v/v) azot suboksid
azot suboksid messer 100 % v/v/1 inhalacija medicinski gas, djelimicno tečni
messer tehnoplin d.o.o - azot suboksid - medicinski gas, djelimicno tečni - 100 % v/v/1 inhalacija - medicinski gas, djelimično tečni sadrži 100 % (v/v) azotsuboksid
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.